

Appl. No. 10/600,266  
Reply to Office Action of September 28, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. **(Currently Amended)** A pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in a ratio by weight of 1:500 to 500:1 and wherein there is no thromboxane A<sub>2</sub> receptor antagonist.

2. **(Original)** The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable excipient.

3. **(Original)** The pharmaceutical composition of claim 1 wherein the 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.

4. **(Original)** The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the hydrochloride.

Appl. No. 10/600,266  
Reply to Office Action of September 28, 2005

**5. (Original)** The pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable salt is the maleate.

**6. (Withdrawn)** A method for the prevention of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

**7. (Withdrawn)** A method according to claim 6, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

**8. (Withdrawn)** A method according to claim 6 or claim 7, in which the warm-blooded animal is a human.

**9. (Withdrawn)** A method for the treatment of diseases caused by thrombus or embolus, comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-

Appl. No. 10/600,266  
Reply to Office Action of September 28, 2005

fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

10. **(Withdrawn)** A method according to claim 9, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

11. **(Withdrawn)** A method according to claim 9 or claim 10, in which the warm-blooded animal is a human.

12. **(Withdrawn)** A method for the treatment of a patient undergoing stenting, angioplasty, and/or to prevent restenosis comprising administering a pharmaceutical composition comprising 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, as active ingredients, in their pharmacologically effective amounts, to a warm-blooded animal.

13. **(Withdrawn)** A method according to claim 12, in which the pharmaceutically acceptable salt is the hydrochloride or maleate.

Appl. No. 10/600,266  
Reply to Office Action of September 28, 2005

**14. (Withdrawn)** A method according to claim 12 or claim 13, in which the warm-blooded animal is a human.

**15. (New)** The pharmaceutical composition according to claim 1, consisting essentially of the 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and the aspirin, and optionally pharmaceutically acceptable excipients.

**16. (New)** The pharmaceutical composition of claim 15 comprising the pharmaceutically acceptable excipient.

**17. (New)** The pharmaceutical composition of claim 15 wherein the 2-acetoxy-5-( $\alpha$ -cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is in the form of a pharmaceutically acceptable salt.

**18. (New)** The pharmaceutical composition according to claim 17, wherein the pharmaceutically acceptable salt is the hydrochloride..

**19. (New)** The pharmaceutical composition according to claim 17, wherein the pharmaceutically acceptable salt is the maleate.